Is Dasatinib on the market?

Dasatinib (Dasatinib) is sold under the brand name Sprycel and other brands. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) in June 2006 and in the European Union by the European Medicines Agency (EMA) in November 2006. The benefits of dasatinib outweigh its risks. The original drug of dasatinib has also been approved by the National Food and Drug Administration for marketing in China and is sold under the name of Cedaxa.

In accelerated- and blast-phase chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), dasatinib frequently induced complete hematologic and cytogenetic remissions, even in imatinib-pretreated patients. However, reduced sentences are often short. Dasatinib is administered at a once-daily dose of 100 mg in chronic phase chronic myelogenous leukemia and 140 mg in Ph+ ALL or blast phase. Side effects of dasatinib are common but mostly moderate and manageable and include cytopenias and pleural effusion.

It is also included in medical insurance and is currently only available for reimbursement to qualified patients. The price of common specifications50mg*60 tablets per box may be around 10,000 yuan, and overseas original drugs are even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).